학술논문
Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial
Document Type
Article
Author
Weller, J.; Tzaridis, T.; Mack, F.; Schaub, C.; Kebir, S.; Herrlinger, U.; Schäfer, N.; Simon, M.; Fimmers, R.; Coch, C.; Steinbach, J.P.; Bähr, O.; Schlegel, U.; Hau, P.; Uhl, M.; Krex, D.; Grauer, O.; Stummer, W.; Goldbrunner, R.; Galldiks, N.; Seidel, C.; Tabatabai, G.; Brehmer, S.; Bullinger, L.; Glas, M.
Source
In: The Lancet Oncology . (The Lancet Oncology, October 2019, 20(10):1444-1453)
Subject
Language
English
ISSN
14745488
14702045
14702045